138 related articles for article (PubMed ID: 25207631)
1. The patent eligibility of personalized medicine technologies.
Octavio L
J Leg Med; 2014; 35(3):423-31. PubMed ID: 25207631
[No Abstract] [Full Text] [Related]
2. CellzDirect gives new hope for patent protection for personalized medicine in the USA.
Ellis J
Pharm Pat Anal; 2017 Jul; 6(4):139-143. PubMed ID: 28696166
[No Abstract] [Full Text] [Related]
3. Does patent protection for personalized medicine still exist in the USA?
Ellis J
Pharm Pat Anal; 2016; 5(2):87-90. PubMed ID: 26889759
[No Abstract] [Full Text] [Related]
4. Patents & the progress of personalized medicine: biomarkers research as lens.
Herder M
Ann Health Law; 2009; 18(2):187-229, 8 p. preceding i. PubMed ID: 21950239
[TBL] [Abstract][Full Text] [Related]
5. Patenting personalized medicines in the UK, Europe and USA.
Parker S; Hall B
Pharm Pat Anal; 2014 Mar; 3(2):163-9. PubMed ID: 24588593
[TBL] [Abstract][Full Text] [Related]
6. Bilski: assessing the impact of a newly invigorated patent-eligibility doctrine on the pharmaceutical industry and the future of personalized medicine.
Holman CM
Curr Top Med Chem; 2010; 10(18):1937-49. PubMed ID: 20615185
[TBL] [Abstract][Full Text] [Related]
7. Patent protection of diagnostic technology: will recent US Supreme Court decisions change patent strategy?
Komatani TS
Pharm Pat Anal; 2015; 4(5):357-62. PubMed ID: 26451906
[No Abstract] [Full Text] [Related]
8. How does emerging patent case law in the US and Europe affect precision medicine?
Aboy M; Liddell K; Crespo C; Cohen IG; Liddicoat J; Gerke S; Minssen T
Nat Biotechnol; 2019 Oct; 37(10):1118-1125. PubMed ID: 31578504
[No Abstract] [Full Text] [Related]
9. Landscape of granted US patents in personalized diagnostics for oncology from 2014 to 2018.
Ouellette SB
Expert Opin Ther Pat; 2019 Mar; 29(3):191-198. PubMed ID: 30712415
[TBL] [Abstract][Full Text] [Related]
10. Personalized medicine: Keep a way open for tailored treatments.
Leek JT; Peng RD; Anderson RR
Nature; 2012 Apr; 484(7394):318. PubMed ID: 22517151
[No Abstract] [Full Text] [Related]
11. The evolving role of biomarker patents in personalized medicine.
Kesselheim AS; Shiu N
Clin Pharmacol Ther; 2014 Feb; 95(2):127-9. PubMed ID: 24448456
[TBL] [Abstract][Full Text] [Related]
12. Patent eligibility of induced pluripotent stem cell theranostics.
Triller Vrtovec K; Vrtovec B
Clin Pharmacol Ther; 2013 Apr; 93(4):318-20. PubMed ID: 23443758
[No Abstract] [Full Text] [Related]
13. US Patent Office issues guidelines on natural product patent eligibility.
Harrison C
Nat Rev Drug Discov; 2014 Apr; 13(4):250. PubMed ID: 24687057
[No Abstract] [Full Text] [Related]
14. Patent first, ask questions later: morality and biotechnology in patent law.
Bagley MA
William Mary Law Rev; 2003 Dec; 45(2):469-547. PubMed ID: 15570677
[TBL] [Abstract][Full Text] [Related]
15. An overview of a recent court challenge to the protection of biomarkers as intellectual property.
Hall SC; Tromp JM; Jortani SA
Clin Chim Acta; 2011 May; 412(11-12):802-5. PubMed ID: 21315704
[TBL] [Abstract][Full Text] [Related]
16. Personalized medicine: its implications and its impact on patents.
Schneider D; Bublak W
Pharm Pat Anal; 2015; 4(6):415-9. PubMed ID: 26580989
[No Abstract] [Full Text] [Related]
17. Patent Eligibility Reform and the Public Health.
Sherkow JS
Milbank Q; 2019 Sep; 97(3):654-658. PubMed ID: 31321802
[No Abstract] [Full Text] [Related]
18. Patent medicine.
Nature; 2011 Sep; 477(7364):249-50. PubMed ID: 21921874
[No Abstract] [Full Text] [Related]
19. Are university researchers at risk for patent infringement?
Yancey A; Stewart CN
Nat Biotechnol; 2007 Nov; 25(11):1225-8. PubMed ID: 17989680
[TBL] [Abstract][Full Text] [Related]
20. Isolated DNA patent ban creates muddy waters for biomarkers and natural products.
Harrison C
Nat Rev Drug Discov; 2013 Aug; 12(8):570-1. PubMed ID: 23903213
[No Abstract] [Full Text] [Related]
[Next] [New Search]
